Sound Income Strategies’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Sound Income Strategies’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13	Closed	-$90	–	1466
2023 Q4	$90	Hold	13	–	–	﹤0.01%	1283
2023 Q3	$122	Hold	13	–	–	﹤0.01%	1117
2023 Q2	$282	Hold	13	–	–	﹤0.01%	1065
2023 Q1	$359	Hold	13	–	–	﹤0.01%	1012
2022 Q4	$472	Hold	13	–	–	﹤0.01%	917
2022 Q3	$3K	Hold	13	–	–	﹤0.01%	672
2022 Q2	$3K	Hold	13	–	–	﹤0.01%	687
2022 Q1	$3K	Hold	13	–	–	﹤0.01%	701
2021 Q4	$2K	Hold	13	–	–	﹤0.01%	741
2021 Q3	$3K	Hold	13	–	–	﹤0.01%	665
2021 Q2	$3K	Hold	13	–	–	﹤0.01%	698
2021 Q1	$3.54K	Hold	13	–	–	﹤0.01%	677
2020 Q4	$5K	Hold	13	–	–	﹤0.01%	596
2020 Q3	$3K	Hold	13	–	–	﹤0.01%	636
2020 Q2	$4K	Hold	13	–	–	﹤0.01%	554
2020 Q1	$3K	Hold	13	–	–	﹤0.01%	549
2019 Q4	$6K	Sell	13 -3	-19%	-$1.06K	﹤0.01%	441
2019 Q3	$5K	Buy	+16	New	+$5.2K	﹤0.01%	440

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

AWP

Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Sound Income Strategies's EIGR Position: Q1 2024 in Review

Sound Income Strategies sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 13 shares — an estimated $90 sold.

Sound Income Strategies first reported a position in EIGR in Q3 2019 and held it in 18 quarters. The position peaked at $6K in Q4 2019. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

Sound Income Strategies reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Sound Income Strategies sold 13 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $90.
Sound Income Strategies first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2019 and held it in 18 quarters.
Sound Income Strategies's Eiger BioPharmaceuticals, Inc. position peaked at $6K in Q4 2019.
24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Sound Income Strategies's 13F filing for Q1 2024, filed 15 Apr 2024.